{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:11:02Z","timestamp":1794003062193,"version":"4.8.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>\n                      Asthma is a heterogeneous disease characterized by chronic airway inflammation and reversible airflow obstruction. Particularly in severe asthma, airway mucus plugs can contribute to substantial and persistent airflow obstruction, despite inhaled corticosteroid and bronchodilator treatment. Consequently, it is important that clinicians assess and treat mucus plugs. Increased mucus production and airway eosinophilia caused by type 2 (T2) inflammation contributes to mucus plug formation and persistence. Several biologics are available to target T2 inflammation in asthma and studies have described their effects on airway mucus plugs using mucus plug scoring derived from computed tomography scans. However, the outcomes, designs and populations of the various studies have not been comprehensively summarized. A literature search was performed to identify primary publications examining the effects of biologics on mucus plugs in patients with moderate-to-severe asthma, organizing studies by design and study population. Three placebo-controlled randomized controlled trials (RCTs) were identified; one RCT of tezepelumab in patients across baseline blood eosinophil counts (BECs) and fractional exhaled nitric oxide (FeNO) levels and two RCTs of dupilumab in those with elevated BECs or sputum eosinophils and\/or elevated FeNO levels. Across these RCTs, biologic treatment decreased mucus plug scores compared with placebo. In the tezepelumab RCT, greater effects were observed in patients with T2-high asthma, highlighting the association between mucus plugging and T2 inflammation. Among T2-high populations, effects were of a similar magnitude across biologics studied. Other biologics (benralizumab, mepolizumab, omalizumab and reslizumab) were evaluated in observational studies without a placebo control, demonstrating reductions in mucus plug scores after treatment. In several studies, decreases in mucus plugs with biologic treatment were associated with improvements in functional outcomes, including pre-bronchodilator forced expiratory volume in 1 second (pre-BD FEV\n                      <jats:sub>1<\/jats:sub>\n                      ), air trapping, ventilation defects assessed by magnetic resonance imaging, asthma control and health-related quality of life. All studies showed residual plugs after biologic intervention, demonstrating a need for further understanding of how best to quantify and characterize mucus plugs to predict their response to treatment and develop optimal, individualised treatment strategies. This review highlights the relevance of assessing and targeting mucus plugs in clinical practice to help optimise patient outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12931-026-03501-z","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T03:24:51Z","timestamp":1768965891000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effectiveness of biologics for reducing occlusive mucus plugs in patients with severe asthma: a systematic review"],"prefix":"10.1186","volume":"27","author":[{"given":"Helena","family":"Aegerter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher E","family":"Brightling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor M","family":"Dunican","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart N","family":"Lambrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Njira L","family":"Lugogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"John D","family":"Newell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Porsbjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Svenningsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew W","family":"Lindsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Nordenmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S","family":"Ambrose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"3501_CR1","unstructured":"Global Initiative for Asthma, Global strategy for asthma management and prevention. 2024. https:\/\/ginasthma.org\/wp-content\/uploads\/2024\/05\/GINA-2024-Strategy-Report-24_05_22_WMS.pdf. (Accessed 6 January 2025)."},{"issue":"2","key":"3501_CR2","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1183\/09031936.00202013","volume":"43","author":"KF Chung","year":"2014","unstructured":"Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, Boulet LP, Brightling C, Chanez P, Dahlen SE, Djukanovic R, Frey U, Gaga M, Gibson P, Hamid Q, Jajour NN, Mauad T, Sorkness RL, Teague WG. International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343\u201373.","journal-title":"Eur Respir J"},{"key":"3501_CR3","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1146\/annurev-pathol-042220-015902","volume":"18","author":"H Aegerter","year":"2023","unstructured":"Aegerter H, Lambrecht BN. The pathology of asthma: what is obstructing our view? Annu Rev Pathol. 2023;18:387\u2013409.","journal-title":"Annu Rev Pathol"},{"issue":"174","key":"3501_CR4","doi-asserted-by":"publisher","first-page":"240221","DOI":"10.1183\/16000617.0221-2024","volume":"33","author":"CE Brightling","year":"2024","unstructured":"Brightling CE, Marone G, Aegerter H, Chanez P, Heffler E, Pavord ID, Rabe KF, Uller L, Dorscheid D. The epithelial era of asthma research: knowledge gaps and future direction for patient care. Eur Respir Rev. 2024;33(174):240221.","journal-title":"Eur Respir Rev"},{"issue":"3","key":"3501_CR5","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1172\/JCI95693","volume":"128","author":"EM Dunican","year":"2018","unstructured":"Dunican EM, Elicker BM, Gierada DS, Nagle SK, Schiebler ML, Newell JD, Raymond WW, Lachowicz-Scroggins ME, Di Maio S, Hoffman EA, Castro M, Fain SB, Jarjour NN, Israel E, Levy BD, Erzurum SC, Wenzel SE, Meyers DA, Bleecker ER, Phillips BR, Mauger DT, Gordon ED, Woodruff PG, Peters MC, Fahy JV. Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. J Clin Invest. 2018;128(3):997\u20131009.","journal-title":"J Clin Invest"},{"issue":"6","key":"3501_CR6","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.chest.2019.02.403","volume":"155","author":"S Svenningsen","year":"2019","unstructured":"Svenningsen S, Haider E, Boylan C, Mukherjee M, Eddy RL, Capaldi DPI, Parraga G, Nair P. CT and functional MRI to evaluate airway mucus in severe asthma. Chest. 2019;155(6):1178\u201389.","journal-title":"Chest"},{"issue":"9","key":"3501_CR7","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1164\/rccm.202110-2265OC","volume":"205","author":"M Tang","year":"2022","unstructured":"Tang M, Elicker BM, Henry T, Gierada DS, Schiebler ML, Huang BK, Peters MC, Castro M, Hoffman EA, Fain SB, Ash SY, Choi J, Hall C, Phillips BR, Mauger DT, Denlinger LC, Jarjour NN, Israel E, Phipatanakul W, Levy BD, Wenzel SE, Bleecker ER, Woodruff PG, Fahy JV, Dunican EM. Mucus plugs persist in Asthma, and changes in mucus plugs associate with changes in airflow over time. Am J Respir Crit Care Med. 2022;205(9):1036\u201345.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"3501_CR8","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.alit.2024.03.001","volume":"73","author":"C Venegas Garrido","year":"2024","unstructured":"Venegas Garrido C, Mukherjee M, Svenningsen S, Nair P. Eosinophil-mucus interplay in severe asthma: implications for treatment with biologicals. Allergol Int. 2024;73(3):351\u201361.","journal-title":"Allergol Int"},{"key":"3501_CR9","doi-asserted-by":"crossref","unstructured":"Liegeois MA, Braunreuther M, Charbit AR, Raymond WW, Tang M, Woodruff PG, Christenson SA, Castro M, Erzurum SC, Israel E, Jarjour NN, Levy BD, Moore WC, Wenzel SE, Fuller GG, Fahy JV. Peroxidase-mediated mucin cross-linking drives pathologic mucus gel formation in IL-13-stimulated airway epithelial cells. JCI Insight. 2024;9(15):e181024.","DOI":"10.1172\/jci.insight.181024"},{"issue":"6","key":"3501_CR10","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1172\/JCI84910","volume":"126","author":"LR Bonser","year":"2016","unstructured":"Bonser LR, Zlock L, Finkbeiner W, Erle DJ. Epithelial tethering of MUC5AC-rich mucus impairs mucociliary transport in asthma. J Clin Invest. 2016;126(6):2367\u201371.","journal-title":"J Clin Invest"},{"key":"3501_CR11","doi-asserted-by":"crossref","unstructured":"Carpenter J, Wang Y, Gupta R, Li Y, Haridass P, Subramani DB, Reidel B, Morton L, Ridley C, O\u2019Neal WK, Buisine MP, Ehre C, Thornton DJ, Kesimer M. Assembly and organization of the N-terminal region of mucin MUC5AC: indications for structural and functional distinction from MUC5B. Proc Natl Acad Sci U S A. 2021;118(39):e2104490118.","DOI":"10.1073\/pnas.2104490118"},{"issue":"6442","key":"3501_CR12","doi-asserted-by":"publisher","first-page":"eaaw4295","DOI":"10.1126\/science.aaw4295","volume":"364","author":"EK Persson","year":"2019","unstructured":"Persson EK, Verstraete K, Heyndrickx I, Gevaert E, Aegerter H, Percier J-M, Deswarte K, Verschueren KHG, Dansercoer A, Gras D, Chanez P, Bachert C, Gon\u00e7alves A, Van Gorp H, De Haard H, Blanchetot C, Saunders M, Hammad H, Savvides SN, Lambrecht BN. Protein crystallization promotes type 2 immunity and is reversible by antibody treatment. Science. 2019;364(6442):eaaw4295.","journal-title":"Science"},{"issue":"Suppl 3","key":"3501_CR13","doi-asserted-by":"publisher","first-page":"S184","DOI":"10.1513\/AnnalsATS.201807-485AW","volume":"15","author":"EM Dunican","year":"2018","unstructured":"Dunican EM, Watchorn DC, Fahy JV. Autopsy and imaging studies of mucus in asthma. Lessons learned about disease mechanisms and the role of mucus in airflow obstruction. Ann Am Thorac Soc. 2018;15(Suppl 3):S184\u201391.","journal-title":"Ann Am Thorac Soc"},{"key":"3501_CR14","doi-asserted-by":"crossref","unstructured":"Khanna K, Tang M, Leung C, Charbit AR, Jackson N, Bleecker ER, Castro M. High airway TSLP levels in asthma associate with higher scores for mucus plugging and air trapping, American Thoracic Society International Conference, San Francisco, USA, 2025.","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A7766"},{"issue":"5","key":"3501_CR15","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1164\/rccm.200903-0392OC","volume":"180","author":"PG Woodruff","year":"2009","unstructured":"Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, Koth LL, Arron JR, Fahy JV. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180(5):388\u201395.","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"3501_CR16","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1172\/JCI200113557","volume":"108","author":"J Laoukili","year":"2001","unstructured":"Laoukili J, Perret E, Willems T, Minty A, Parthoens E, Houcine O, Coste A, Jorissen M, Marano F, Caput D, Tournier F. IL-13 alters mucociliary differentiation and ciliary beating of human respiratory epithelial cells. J Clin Invest. 2001;108(12):1817\u201324.","journal-title":"J Clin Invest"},{"issue":"12","key":"3501_CR17","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1164\/rccm.202307-1266OC","volume":"210","author":"J Boomer","year":"2024","unstructured":"Boomer J, Choi J, Alsup A, McGregor MC, Lieu J, Johnson C, Hall C, Shi X, Kim T, Goss C, Lew D, Christensen S, Woodruff P, Hastie A, Mauger D, Wenzel SE, Hoffman E, Schechtman KB, Castro M. Increased Muc5AC and decreased ciliated cells in severe asthma partially restored by Inhibition of IL-4R\u03b1 receptor. Am J Respir Crit Care Med. 2024;210(12):1409\u201320.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"3501_CR18","doi-asserted-by":"publisher","first-page":"3900","DOI":"10.1038\/s41467-024-48034-5","volume":"15","author":"JL Everman","year":"2024","unstructured":"Everman JL, Sajuthi SP, Liegeois MA, Jackson ND, Collet EH, Peters MC, Chioccioli M, Moore CM, Patel BB, Dyjack N, Powell R, Rios C, Montgomery MT, Eng C, Elhawary JR, Mak ACY, Hu D, Huntsman S, Salazar S, Feriani L, Fairbanks-Mahnke A, Zinnen GL, Michel CR, Gomez J, Zhang X, Medina V, Chu HW, Cicuta P, Gordon ED, Zeitlin P, Ortega VE, Reisdorph N, Dunican EM, Tang M, Elicker BM, Henry TS, Bleecker ER, Castro M, Erzurum SC, Israel E, Levy BD, Mauger DT, Meyers DA, Sumino K, Gierada DS, Hastie AT, Moore WC, Denlinger LC, Jarjour NN, Schiebler ML, Wenzel SE, Woodruff PG, Rodriguez-Santana J, Pearson CG, Burchard EG, Fahy JV, Seibold MA. A common polymorphism in the intelectin-1 gene influences mucus plugging in severe asthma. Nat Commun. 2024;15(1):3900.","journal-title":"Nat Commun"},{"issue":"10","key":"3501_CR19","doi-asserted-by":"publisher","first-page":"EVIDoa2300135","DOI":"10.1056\/EVIDoa2300135","volume":"2","author":"LH Nordenmark","year":"2023","unstructured":"Nordenmark LH, Hellqvist \u00c5, Emson C, Diver S, Porsbjerg C, Griffiths JM, Newell JD, Peterson S, Pawlikowska B, Parnes JR, Megally A, Colice G, Brightling CE. Tezepelumab and mucus plugs in patients with moderate-to-severe asthma. NEJM Evid. 2023;2(10):EVIDoa2300135.","journal-title":"NEJM Evid"},{"issue":"1","key":"3501_CR20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1165\/rcmb.2020-0168OC","volume":"64","author":"RS Linssen","year":"2021","unstructured":"Linssen RS, Chai G, Ma J, Kummarapurugu AB, van Woensel JBM, Bem RA, Kaler L, Duncan GA, Zhou L, Rubin BK, Xu Q. Neutrophil extracellular traps increase airway mucus viscoelasticity and slow mucus particle transit. Am J Respir Cell Mol Biol. 2021;64(1):69\u201378.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"1","key":"3501_CR21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1172\/JCI200422288","volume":"114","author":"MA Matthay","year":"2004","unstructured":"Matthay MA, Clements JA. Coagulation-dependent mechanisms and asthma. J Clin Invest. 2004;114(1):20\u20133.","journal-title":"J Clin Invest"},{"key":"3501_CR22","unstructured":"Netter FH. Netter atlas of human anatomy: classic regional approach, 8th ed., Elsevier, Philadelphia, 2023."},{"issue":"6","key":"3501_CR23","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.resinv.2024.08.014","volume":"62","author":"N Tanabe","year":"2024","unstructured":"Tanabe N, Nakagawa H, Sakao S, Ohno Y, Shimizu K, Nakamura H, Hanaoka M, Nakano Y, Hirai T. Lung imaging in COPD and asthma. Respir Investig. 2024;62(6):995\u20131005.","journal-title":"Respir Investig"},{"issue":"1","key":"3501_CR24","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1148\/radiol.2021204616","volume":"303","author":"DG Mummy","year":"2022","unstructured":"Mummy D.G., Dunican E.M., Carey K.J., Evans M.D., Elicker B.M., Jr. Newell J.D., Gierada D.S., Nagle S.K., Schiebler M.L., Sorkness R.L., Jarjour N.N., Denlinger L.C., Fahy J.V., Fain S.B. Mucus plugs in asthma at CT associated with regional ventilation defects at (3)He MRI. Radiology. 2022;303(1):184\u201390.","journal-title":"Radiology"},{"issue":"4","key":"3501_CR25","doi-asserted-by":"publisher","first-page":"2301397","DOI":"10.1183\/13993003.01397-2023","volume":"63","author":"RJ Russell","year":"2024","unstructured":"Russell RJ, Boulet LP, Brightling CE, Pavord ID, Porsbjerg C, Dorscheid D, Sverrild A. The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma. Eur Respir J. 2024;63(4):2301397.","journal-title":"Eur Respir J"},{"issue":"18","key":"3501_CR26","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1056\/NEJMoa2024257","volume":"385","author":"ME Wechsler","year":"2021","unstructured":"Wechsler ME, Ruddy MK, Pavord ID, Israel E, Rabe KF, Ford LB, Maspero JF, Abdulai RM, Hu C-C, Martincova R, Jessel A, Nivens MC, Amin N, Weinreich DM, Yancopoulos GD, Goulaouic H. Efficacy and safety of itepekimab in patients with moderate-to-severe asthma. N Engl J Med. 2021;385(18):1656\u201368.","journal-title":"N Engl J Med"},{"issue":"3","key":"3501_CR27","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jaci.2021.03.044","volume":"148","author":"SG Kelsen","year":"2021","unstructured":"Kelsen SG, Agache IO, Soong W, Israel E, Chupp GL, Cheung DS, Theess W, Yang X, Staton TL, Choy DF, Fong A, Dash A, Dolton M, Pappu R, Brightling CE. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial. J Allergy Clin Immunol. 2021;148(3):790\u20138.","journal-title":"J Allergy Clin Immunol"},{"key":"3501_CR28","doi-asserted-by":"crossref","unstructured":"Deiteren A, Krupka E, Bontinck L, Imberdis K, Conickx G, Bas S, Patel N, Staudinger HW, Suratt BT. A proof-of-mechanism trial in asthma with lunsekimig, a bispecific NANOBODY molecule. Eur Respir J. 2025;65(4):2401461.","DOI":"10.1183\/13993003.01461-2024"},{"issue":"3","key":"3501_CR29","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S2213-2600(24)00362-X","volume":"13","author":"M Castro","year":"2025","unstructured":"Castro M, Papi A, Porsbjerg C, Lugogo NL, Brightling CE, Gonz\u00e1lez-Barcala F-J, Bourdin A, Ostrovskyy M, Staevska M, Chou P-C, Duca L, Pereira AM, Fogarty C, Nadama R, Zhang M, Rodrigues A, Soler X, Sacks HJ, Deniz Y, Rowe PJ, de Prado L, G\u00f3mez JA, Jacob-Nara. Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2025;13(3):208\u201320.","journal-title":"Lancet Respir Med"},{"issue":"9","key":"3501_CR30","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1164\/rccm.202306-1102LE","volume":"208","author":"S Svenningsen","year":"2023","unstructured":"Svenningsen S, Kjarsgaard M, Haider E, Venegas C, Konyer N, Friedlander Y, Nasir N, Boylan C, Kirby M, Nair P. Effects of dupilumab on mucus plugging and ventilation defects in patients with moderate-to-severe asthma: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med. 2023;208(9):995\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"3501_CR31","first-page":"A6371","volume":"209","author":"T Koya","year":"2024","unstructured":"Koya T, Murai Y, Tanaka M, Matsuda T, Muramatsu N, Naramoto S, Aoki A, Shima K, Kimura Y, Hasegawa T, Kikuchi T. Mucus plugs associated with dupilumab induction in severe asthma. Am J Respir Crit Care Med. 2024;209:A6371.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"3501_CR32","doi-asserted-by":"publisher","first-page":"673","DOI":"10.3348\/kjr.2024.0110","volume":"25","author":"HN Lee","year":"2024","unstructured":"Lee HN, An J, Lee M, Hwang HJ, Choe J, Yoon J, Lee JH, Kim MH, Cho YJ, Lee SM, Kim TB, Seo JB. Assessment of treatment response in patients with severe asthma using visual and quantitative analysis of chest CT. Korean J Radiol. 2024;25(7):673\u201383.","journal-title":"Korean J Radiol"},{"issue":"8","key":"3501_CR33","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1159\/000530392","volume":"184","author":"N Sakai","year":"2023","unstructured":"Sakai N, Koya T, Murai Y, Tsubokawa F, Tanaka K, Naramoto S, Aoki A, Shima K, Kimura Y, Watanabe S, Hasegawa T, Kikuchi T. Effect of benralizumab on mucus plugs in severe eosinophilic asthma. Int Arch Allergy Immunol. 2023;184(8):783\u201391.","journal-title":"Int Arch Allergy Immunol"},{"issue":"3","key":"3501_CR34","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.chest.2022.03.003","volume":"162","author":"MJ McIntosh","year":"2022","unstructured":"McIntosh MJ, Kooner HK, Eddy RL, Jeimy S, Licskai C, Mackenzie CA, Svenningsen S, Nair P, Yamashita C, Parraga G. Asthma control, airway mucus, and 12 9 Xe MRI ventilation after a single benralizumab dose. Chest. 2022;162(3):520\u201333.","journal-title":"Chest"},{"issue":"1","key":"3501_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.chest.2023.02.009","volume":"164","author":"MJ McIntosh","year":"2023","unstructured":"McIntosh MJ, Kooner HK, Eddy RL, Wilson A, Serajeddini H, Bhalla A, Licskai C, Mackenzie CA, Yamashita C, Parraga G. CT mucus score and 129XE MRI ventilation defects after 2.5 years\u2019 anti-IL-5R. Chest. 2023;164(1):27\u201338.","journal-title":"Chest"},{"issue":"3","key":"3501_CR36","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.alit.2024.02.002","volume":"73","author":"T Tajiri","year":"2024","unstructured":"Tajiri T, Suzuki M, Nishiyama H, Ozawa Y, Kurokawa R, Takeda N, Ito K, Fukumitsu K, Kanemitsu Y, Mori Y, Fukuda S, Uemura T, Ohkubo H, Takemura M, Maeno K, Ito Y, Oguri T, Izuhara K, Niimi A. Efficacy of dupilumab for airway hypersecretion and airway wall thickening in patients with moderate-to-severe asthma: A prospective, observational study. Allergology Int. 2024;73(3):406\u201315.","journal-title":"Allergology Int"},{"issue":"1","key":"3501_CR37","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s12931-024-02998-6","volume":"25","author":"M Caminati","year":"2024","unstructured":"Caminati M, Vatrella A, Rogliani P, Carpagnano E, Spanevello A, Senna G. Tezepelumab for severe asthma: elevating current practice to recognize epithelial driven profiles. Respir Res. 2024;25(1):367.","journal-title":"Respir Res"},{"issue":"1","key":"3501_CR38","first-page":"1","volume":"33","author":"L P\u00e9rez de Llano","year":"2023","unstructured":"P\u00e9rez de Llano L, Cisneros C, Dom\u00ednguez-Ortega J, Mart\u00ednez-Morag\u00f3n E, Olaguibel JM, Plaza V, Quirce S, D\u00e1vila I. Response to monoclonal antibodies in asthma: definitions, potential reasons for failure, and therapeutic options for suboptimal response. J Investig Allergol Clin Immunol. 2023;33(1):1\u201313.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"3501_CR39","doi-asserted-by":"crossref","unstructured":"Santus P, Radovanovic D, Chiumello DA. Mucins and asthma: are we headed to the revolutionary road? J Clin Med. 2019;8(11):1955.","DOI":"10.3390\/jcm8111955"},{"issue":"8","key":"3501_CR40","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/resp.14520","volume":"28","author":"PA Shah","year":"2023","unstructured":"Shah PA, Brightling C. Biologics for severe asthma \u2013 which, when and why? Respirology. 2023;28(8):709\u201321.","journal-title":"Respirology"},{"issue":"2","key":"3501_CR41","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/all.16382","volume":"80","author":"G Varricchi","year":"2025","unstructured":"Varricchi G, Poto R, Lommatzsch M, Brusselle G, Braido F, Virchow JC, Canonica GW. Biologics and airway remodeling in asthma: early, late, and potential preventive effects. Allergy. 2025;80(2):408\u201322.","journal-title":"Allergy"},{"issue":"6","key":"3501_CR42","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1080\/17476348.2022.2096593","volume":"16","author":"D Watchorn","year":"2022","unstructured":"Watchorn D, Menzies-Gow A. Investigational approaches for unmet need in severe asthma. Expert Rev Respir Med. 2022;16(6):661\u201378.","journal-title":"Expert Rev Respir Med"},{"key":"3501_CR43","unstructured":"AstraZeneca. Data on file (2024)."},{"key":"3501_CR44","doi-asserted-by":"crossref","unstructured":"Huang BK, Elicker BM, Henry TS, Kallianos KG, Hahn LD, Tang M, Heng F, McCulloch CE, Bhakta NR, Majumdar S, Choi J, Denlinger LC, Fain SB, Hastie AT, Hoffman EA, Israel E, Jarjour NN, Levy BD, Mauger DT, Sumino K, Wenzel SE, Castro M, Woodruff PG, Fahy JV, Sarp F. Persistent mucus plugs in proximal airways are consequential for airflow limitation in asthma. JCI Insight. 2024;9(3):e174124.","DOI":"10.1172\/jci.insight.174124"},{"issue":"1018","key":"3501_CR45","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1136\/pgmj.2009.091041","volume":"86","author":"P Goeminne","year":"2010","unstructured":"Goeminne P, Dupont L. Non-cystic fibrosis bronchiectasis: diagnosis and management in 21st century. Postgrad Med J. 2010;86(1018):493\u2013501.","journal-title":"Postgrad Med J"},{"issue":"2","key":"3501_CR46","first-page":"S177","volume":"13","author":"MA Mall","year":"2016","unstructured":"Mall MA. Unplugging mucus in cystic fibrosis and chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2016;13(2):S177\u201385.","journal-title":"Ann Am Thorac Soc"},{"issue":"3","key":"3501_CR47","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.alit.2024.06.001","volume":"73","author":"K Asano","year":"2024","unstructured":"Asano K. Mucus plugs in severe asthma and related airway diseases. Allergol Int. 2024;73(3):349\u201350.","journal-title":"Allergol Int"},{"issue":"8","key":"3501_CR48","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1164\/rccm.202006-2248OC","volume":"203","author":"EM Dunican","year":"2021","unstructured":"Dunican EM, Elicker BM, Henry T, Gierada DS, Schiebler ML, Anderson W, Barjaktarevic I, Barr RG, Bleecker ER, Boucher RC, Bowler R, Christenson SA, Comellas A, Cooper CB, Couper D, Criner GJ, Dransfield M, Doerschuk CM, Drummond MB, Hansel NN, Han MK, Hastie AT, Hoffman EA, Krishnan JA, Lazarus SC, Martinez FJ, McCulloch CE, O\u2019Neal WK, Ortega VE, Paine R, Peters S, Schroeder JD, Woodruff PG, Fahy JV. Mucus plugs and emphysema in the pathophysiology of airflow obstruction and hypoxemia in smokers. Am J Respir Crit Care Med. 2021;203(8):957\u201368.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"3501_CR49","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1152\/physrev.00004.2021","volume":"102","author":"DB Hill","year":"2022","unstructured":"Hill DB, Button B, Rubinstein M, Boucher RC. Physiology and pathophysiology of human airway mucus. Physiol Rev. 2022;102(4):1757\u2013836.","journal-title":"Physiol Rev"},{"issue":"Suppl 2","key":"3501_CR50","first-page":"A67","volume":"79","author":"L Nordenmark","year":"2024","unstructured":"Nordenmark L, Guller P, Reid F, Doffman S, Sepp\u00e4l\u00e4 U, Psallidas I, Moate R, Smith R, Kiraga J, Kell C, Belvisi M, Pandya H, Singh D. S91\u2005Tozorakimab (anti-IL-33 mAb) reduces mucus plugging in COPD: an imaging sub-study in the FRONTIER-4 phase 2a COPD trial. Thorax. 2024;79(Suppl 2):A67\u20138.","journal-title":"Thorax"},{"issue":"5","key":"3501_CR51","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1164\/rccm.200212-1437OC","volume":"168","author":"T Shimizu","year":"2003","unstructured":"Shimizu T, Shimizu S, Hattori R, Gabazza EC, Majima Y. In vivo and in vitro effects of macrolide antibiotics on mucus secretion in airway epithelial cells. Am J Respir Crit Care Med. 2003;168(5):581\u20137.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"3501_CR52","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.rmed.2012.12.019","volume":"107","author":"S Simoens","year":"2013","unstructured":"Simoens S, Laekeman G, Decramer M. Preventing COPD exacerbations with macrolides: a review and budget impact analysis. Respir Med. 2013;107(5):637\u201348.","journal-title":"Respir Med"},{"issue":"2","key":"3501_CR53","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1136\/thorax-2024-221928","volume":"80","author":"T van der Veer","year":"2025","unstructured":"van der Veer T, Andrinopoulou ER, Braunstahl GJ, Charbonnier JP, Kim V, Latisenko R, Lynch DA, Tiddens H. Association between automatic AI-based quantification of airway-occlusive mucus plugs and all-cause mortality in patients with COPD. Thorax. 2025;80(2):105\u20138.","journal-title":"Thorax"},{"issue":"9","key":"3501_CR54","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.acra.2010.04.019","volume":"17","author":"BL Odry","year":"2010","unstructured":"Odry BL, Kiraly AP, Godoy MC, Ko J, Naidich DP, Novak CL, Lerallut JF. Automated CT scoring of airway diseases: preliminary results. Acad Radiol. 2010;17(9):1136\u201345.","journal-title":"Acad Radiol"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-026-03501-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03501-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03501-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T14:03:12Z","timestamp":1770991392000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12931-026-03501-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3501"],"URL":"https:\/\/doi.org\/10.1186\/s12931-026-03501-z","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"10 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. Ethics approval is not applicable as this article did not involve human or non-human animal participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study was funded by AstraZeneca and Amgen Inc. HA is supported by a grant from the Research Foundation Flanders (FWO) and has received speaker fees from AstraZeneca and GSK. CEB has received grants and consultancy fees from 4D Pharma, Areteia Therapeutics, AstraZeneca, Chiesi, Genentech, Global Access Diagnostics (formerly Mologic), GSK, Novartis, Regeneron Pharmaceuticals, Roche and Sanofi. MC has received grants\/research support from the American Lung Association, AstraZeneca, Gala Therapeutics, Genentech, GSK, National Institutes of Health (NIH), Novartis, Patient-Centered Outcomes Research Institute, PULMATRiX, Sanofi-Aventis, Shionogi and Theravance Biopharma; has received consultancy fees from Allakos, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Genentech, Merck, Novartis, OM Pharma, Pioneering Medicines, Regeneron Pharmaceuticals, Sanofi and Teva Pharmaceuticals; and has received royalties from Aer Therapeutics. EMD has nothing to disclose. BNL is supported by grants from the European Research Council, Flanders Institute of Biotechnology (VIB), Ghent University and Research Foundation Flanders (FWO). He has received consulting fees from Argenx, AstraZeneca, GSK and Sanofi. NLL has received consultancy fees from AbbVie, Amgen, Apogee, AstraZeneca, Avillion, Foresee, Genentech, GSK, Niox, Novartis, Regeneron, Sanofi and Teva; honoraria for non-speaker bureau presentations from GSK, Teva Pharmaceuticals, Sanofi\/Regeneron and AstraZeneca; and travel support from AstraZeneca, Sanofi, Teva Pharmaceuticals, Regeneron and GSK; her institution has received research support from Amgen, AstraZeneca, Avillion, Bellus, Evidera, Gossamer Bio, Genentech, GSK, Janssen, Regeneron, Roche, Sanofi, Novartis and Teva Pharmaceuticals. She is an honorary faculty member of the Observational and Pragmatic Research Institute (OPRI) but does not receive compensation for this role. JDN Jr. is a medical adviser for VIDA Diagnostics; has received consultancy fees from VIDA Diagnostics; is supported by grants from the National Institutes of Health (NIH) through the University of Iowa; and has received book royalties from Elsevier Publishing. CP has received grants and consultancy fees from ALK-Abell\u00f3, AstraZeneca, Chiesi, GSK, Novartis, Sanofi and Teva Pharmaceuticals. SS has received grants\/research support from Cyclomedica, Genentech and Trudell Medical; and has received consulting and\/or speaker fees from Cyclomedica, AstraZeneca, Novartis, GSK, Sanofi and Polarean Imaging. DC and CSA are employees of AstraZeneca and may own stock or stock options in AstraZeneca. AWL is an employee of Amgen and owns stock in Amgen. LN was an employee of AstraZeneca at the time of writing this review and may own stock or stock options in AstraZeneca.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"69"}}